TW200633720A - Medicinal composition for diabetic - Google Patents

Medicinal composition for diabetic

Info

Publication number
TW200633720A
TW200633720A TW094143827A TW94143827A TW200633720A TW 200633720 A TW200633720 A TW 200633720A TW 094143827 A TW094143827 A TW 094143827A TW 94143827 A TW94143827 A TW 94143827A TW 200633720 A TW200633720 A TW 200633720A
Authority
TW
Taiwan
Prior art keywords
diabetic
medicinal composition
inhibit
effort
side effects
Prior art date
Application number
TW094143827A
Other languages
English (en)
Inventor
Taishi Yoshida
Akira Okuno
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of TW200633720A publication Critical patent/TW200633720A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW094143827A 2004-12-13 2005-12-12 Medicinal composition for diabetic TW200633720A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2004359587 2004-12-13

Publications (1)

Publication Number Publication Date
TW200633720A true TW200633720A (en) 2006-10-01

Family

ID=36587799

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094143827A TW200633720A (en) 2004-12-13 2005-12-12 Medicinal composition for diabetic

Country Status (8)

Country Link
US (1) US20070259928A1 (zh)
EP (1) EP1857118A1 (zh)
KR (1) KR20070086007A (zh)
CN (1) CN101119748A (zh)
BR (1) BRPI0519006A2 (zh)
CA (1) CA2590883A1 (zh)
TW (1) TW200633720A (zh)
WO (1) WO2006064744A1 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5856980B2 (ja) 2010-01-27 2016-02-10 アリーナ ファーマシューティカルズ， インコーポレイテッド （Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸およびその塩の調製のためのプロセス
KR101871011B1 (ko) * 2010-09-22 2018-06-25 아레나 파마슈티칼스, 인크. Ｇｐｒ１１９ 수용체의 조절제 및 그와 관련된 장애의 치료
UA126268C2 (uk) 2015-01-06 2022-09-14 Арена Фармасьютікалз, Інк. СПОСОБИ ЛІКУВАННЯ СТАНІВ, ПОВ'ЯЗАНИХ З РЕЦЕПТОРОМ S1P<sub>1 </sub>
EA201890096A1 (ru) 2015-06-22 2018-08-31 Арена Фармасьютикалз, Инк. КРИСТАЛЛИЧЕСКАЯ L-АРГИНИНОВАЯ СОЛЬ (R)-2-(7-(4-ЦИКЛОПЕНТИЛ-3-(ТРИФТОРМЕТИЛ)БЕНЗИЛОКСИ)-1,2,3,4-ТЕТРАГИДРОЦИКЛОПЕНТА[b]ИНДОЛ-3-ИЛ)УКСУСНОЙ КИСЛОТЫ (СОЕДИНЕНИЯ 1) ДЛЯ ПРИМЕНЕНИЯ ПРИ РАССТРОЙСТВАХ, СВЯЗАННЫХ С S1P-РЕЦЕПТОРОМ
US11534424B2 (en) 2017-02-16 2022-12-27 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6051189A (ja) * 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
FR2738741B1 (fr) * 1995-09-19 1997-12-05 Oreal Composition pour la teinture des fibres keratiniques, contenant un antagoniste de substance p
WO2000014095A1 (en) * 1998-09-09 2000-03-16 Metabasis Therapeutics, Inc. Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase
US6756360B1 (en) * 1998-12-24 2004-06-29 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes
WO2000038666A2 (en) * 1998-12-24 2000-07-06 Metabasis Therapeutics, Inc. A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES
US7205404B1 (en) * 1999-03-05 2007-04-17 Metabasis Therapeutics, Inc. Phosphorus-containing prodrugs
TWI284533B (en) * 1999-05-24 2007-08-01 Sankyo Co Pharmaceutical composition for treating hyperglycemia, impaired glucose tolerance, diabetes complications and for improving insulin resistant
WO2001047935A2 (en) * 1999-12-22 2001-07-05 Metabasis Therapeutics, Inc. Novel bisamidate phosphonate prodrugs
IL151248A0 (en) * 2000-03-08 2003-04-10 Metabasis Therapeutics Inc Novel aryl fructose-1,6-bisphosphatase inhibitors
US7563774B2 (en) * 2000-06-29 2009-07-21 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
PL365779A1 (en) * 2000-07-06 2005-01-10 Metabasis Therapeutics, Inc. A combination of fbpase inhibitors and antidiabetic agents useful for the treatment of diabetes
US6790459B1 (en) * 2000-11-03 2004-09-14 Andrx Labs, Llc Methods for treating diabetes via administration of controlled release metformin
EP1723948A1 (en) * 2000-11-03 2006-11-22 Andrx Labs, LLC Controlled release compositions of biguanide with less side effects and treatment regimen thereof
US6866866B1 (en) * 2000-11-03 2005-03-15 Andrx Labs, Llc Controlled release metformin compositions
AU2003252676A1 (en) * 2002-07-23 2004-02-09 Sankyo Company, Limited Preventive for the onset of diabetes

Also Published As

Publication number Publication date
EP1857118A1 (en) 2007-11-21
CN101119748A (zh) 2008-02-06
KR20070086007A (ko) 2007-08-27
CA2590883A1 (en) 2006-06-22
BRPI0519006A2 (pt) 2008-12-23
WO2006064744A1 (ja) 2006-06-22
US20070259928A1 (en) 2007-11-08

Similar Documents

Publication Publication Date Title
TN2011000176A1 (en) Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug
WO2008022256A3 (en) Methods and compositions for preventing or treating age-related diseases
IL179515A0 (en) Method of administering and using vegf inhibitors for the treatment of human cancer
GB2431346C (en) A combination composition comprising paracetamol and ibuprofen
MX2009006007A (es) Profarmacos y metodos para hacer y usar los mismos.
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
AU2008267058A8 (en) Treatment of pulmonary hypertension with carbonic anhydrase inhibitors in combination with a sympathomimetic amine
HK1091127A1 (en) Compounds and methods for downregulating the effects of tgf-beta
IL175014A0 (en) Method of administering therapeutic injections
SG158863A1 (en) Intravenous formulations of pde-5 inhibitors
WO2007149782A3 (en) Selective inhibitors for transferases
WO2008042480A3 (en) Epoxide inhibitors of cysteine proteases
TW200633720A (en) Medicinal composition for diabetic
MXPA05012358A (es) Combinacion farmaceutica que comprende modafinilo y otra droga.
UA88655C2 (ru) S-миртазапин для лечения прилива крови
EP1503748A4 (en) DRUGS TO REDUCE TAXAN-INDUCED NEUROTOXICITY
TNSN08385A1 (en) Delayed-release glucocorticoid treatment of rheumatoid disease
MXPA03001227A (es) Composiciones neuroprotectoras de 2-piridinamina y metodos relacionados.
WO2005081972A3 (en) Maleiimide anti-tumor phosphatase inhibitors
TW200503666A (en) Treatment of type 1 diabetes with pde5 inhibitors
TW200633702A (en) Medicinal composition containing fbpase inhibitor
TW200603791A (en) Compounds and compositions as cathepsin S inhibitors
WO2006042277A3 (en) Extended release compositions of proton pump inhibitors
TW200738245A (en) Pharmaceutical composition containing FBPase inhibitor
TW200738266A (en) Pharmaceutical agent containing insulin resistance improving agent